# Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial

> **NCT07274384** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Università Vita-Salute San Raffaele** · enrollment: 74 (estimated)

## Conditions studied

- NSCLC (Non-small Cell Lung Cancer)
- Hyperprogression

## Interventions

- **COMBINATION_PRODUCT:** chemotherapy plus cemiplimab
- **DRUG:** Cemiplimab

## Key facts

- **NCT ID:** NCT07274384
- **Lead sponsor:** Università Vita-Salute San Raffaele
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2029-12-31
- **Final completion:** 2030-06-01
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07274384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07274384, "Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07274384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*